ArticleMagnetic resonance in medicine2011
Protein polymer MRI contrast agents: Longitudinal analysis of biomaterials in vivo.
Article in Magnetic resonance in medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Biodegradable Polyesters: Approaches to Increase Degradation Rates for Biomedical Applications.ACS macro letters · 2025Review
- X-Ray Visible Protein Scaffolds by Bulk Iodination.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Effect of Nanoparticle Weight on the Cellular Uptake and Drug Delivery Potential of PLGA Nanoparticles.ACS omega · 2023Article
- Cyclodextrins: promising scaffolds for MRI contrast agents.RSC advances · 2021Review
- Characterization of a novel MR-detectable nanoantioxidant that mitigates the recall immune response.NMR in biomedicine · 2016Article
- X-ray Phase Contrast Allows Three Dimensional, Quantitative Imaging of Hydrogel Implants.Annals of biomedical engineering · 2016Article
- Infection-resistant MRI-visible scaffolds for tissue engineering applications.BioImpacts : BI · 2016Article
- Gd(III)-labeled peptide nanofibers for reporting on biomaterial localization in vivo.ACS nano · 2014Article
- Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2014Review
- Controlled intracellular self-assembly of gadolinium nanoparticles as smart molecular MR contrast agents.Scientific reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Despite recent advances in tissue engineering to regenerate biological function by combining cells with material supports, development is hindered by inadequate techniques for characterizing biomaterials in vivo. Magnetic resonance imaging is a tomographic technique with high temporal and spatial resolution and represents an excellent imaging modality for longitudinal noninvasive assessment of biomaterials in vivo. To distinguish biomaterials from surrounding tissues for magnetic resonance imaging, protein polymer contrast agents were developed and incorporated into hydrogels. In vitro and in vivo images of protein polymer hydrogels, with and without covalently incorporated protein polymer contrast agents, were acquired by magnetic resonance imaging. T(1) values of the labeled gels were consistently lower when protein polymer contrast agents were included. As a result, the protein polymer contrast agent hydrogels facilitated fate tracking, quantification of degradation, and detection of immune response in vivo. For the duration of the in vivo study, the protein polymer contrast agent-containing hydrogels could be distinguished from adjacent tissues and from the foreign body response surrounding the gels. The hydrogels containing protein polymer contrast agent have a contrast-to-noise ratio 2-fold greater than hydrogels without protein polymer contrast agent. In the absence of the protein polymer contrast agent, hydrogels cannot be distinguished by the end of the gel lifetime.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.